LTIP and SAYE option grant

Quantum Pharma Plc

("Quantum" or the "Company")

Grant of LTIP options

and

Grant of SAYE options under Greek sub-plan

Quantum Pharma Plc (AIM: QP.), the growing, service-led niche pharmaceutical manufacturer, developer and supplier to the health and care sectors, announces that on 18 July 2016, it granted nil-cost options over 2,218,057 Ordinary Shares of 10p each ("Ordinary Shares"), representing approximately 1.77% of the current issued share capital, in accordance with the rules of the Quantum Long Term Incentive Plan ("LTIP") 2014. The Company also announces that on 18 July 2016, pursuant to a sub-plan of the Quantum Pharma plc Save-As-You-Earn ("SAYE") Plan, the Company has granted options, under which employees based at the Company's subsidiary, Lamda, in Greece have been offered the opportunity to participate in the future growth of the Company.

The LTIP options have been granted to key members of the senior executive and senior management teams. The options are subject to performance targets measured over three financial years ending on 31 January 2019 and are expected to vest on the later of 18 July 2019 and the date when the Remuneration Committee determines the extent to which the performance targets have been achieved.

Within the above LTIP grant, an award has been made to Chris Rigg, Chief Financial Officer, of a nil-cost option over 446,281 Ordinary Shares. Following this award, Chris Rigg has an interest in 15,000 Ordinary Shares representing 0.012% of the current issued share capital and options over 696,281 Ordinary Shares.

As part of the SAYE Plan, Greek based employees were invited to subscribe for options over the Company's Ordinary Shares with an exercise price of 54.94 pence, a 20% discount to the average closing middle market price of the Company's Ordinary Shares on 14, 15 and 16 June 2016, the three trading days prior to the invitation to participate was made. The options have a contract start date of 1 September 2016 and are exercisable between 1 September 2019 and 28 February 2020.

A total of 5 employees elected to participate, and pursuant to these elections a total of 123,490 options over Ordinary Shares have been issued, representing approximately 0.10% of the current issued share capital.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

- Ends -

For further information:

Notes to Editors

Quantum Pharma Plc is a service-led, niche pharmaceutical developer, manufacturer and supplier to the retail pharmacy, pharmaceutical wholesaler, hospital, homecare and care home markets. Quantum Pharma operates through three divisions, offering a portfolio of innovative and complementary products and services.

Specials comprises four business units (Quantum Pharmaceutical, UL Medicines, NuPharm and Quantum Aseptics Services), which manufacture, procure and supply unlicensed medicines (specials) and special obtains. In response to a request from a prescriber for a bespoke medicine or special product to optimise patient treatment, the division manufactures, procures and supplies bespoke specials; batch made specials; aseptically prepared sterile intravenous medicines; imported medicines and special obtain products. With an expansive portfolio of products, Quantum is a trusted partner to the majority of large retail pharmacy chains in the UK, as well as pharmaceutical wholesalers, hospitals, independent pharmacies and dispensing doctors.  The division offers an unrivalled and constantly expanding range of products. It has a customer-focused, service-driven business model, which provides shorter lead times than any of its competitors.

Niche Pharmaceuticals comprises three business units (Colonis, Lamda and PERN Consumer Products) which develop and commercialise niche pharmaceuticals. This division is a product development and commercialisation business focusing on taking niche drugs through the regulatory pathway to achieve regulated status (licensed product or medical device). The division uses the excellent visibility of trends in the UK pharmacy and hospital markets gained through our Specials and Medication Adherence divisions, to allow early identification of the market opportunity to take products from unlicensed (special) status to licensed status. The division has a growing portfolio and pipeline of products that fit this unlicensed to licensed pathway, as well as complementary generic, generic plus or medical devices intended to meet unmet patient needs across a number of therapeutic areas.

Medication Adherence comprises two business units (Biodose® and Biodose Services®) which provide products and services to enhance the likelihood of a patient adhering to a medication regime, patient-focused homecare services and services to pharmaceutical companies. It owns Biodose®, the only medication delivery system on the market that accommodates both liquid and solid doses. Biodose Connect™ takes patient safety and adherence to the next level by enabling remote monitoring of adherence to medication regimes. The division also operates a range of specialist patient-focused homecare services to the NHS, private clinics and pharmaceutical companies across the UK and provides the Group with exposure to the homecare and supported living sectors of the care pathway complementing the focus of the remainder of the Group.

For further information, please visit www.quantumpharmaplc.com.